We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 01, 2020

Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease

The Lancet

 

Additional Info

The Lancet
Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy Versus Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease (IMMUNED): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Lancet 2020 May 16;395(10236)1558-1568, L Zimmer, E Livingstone, JC Hassel, M Fluck, T Eigentler, C Loquai, S Haferkamp, R Gutzmer, F Meier, P Mohr, A Hauschild, B Schilling, C Menzer, F Kieker, E Dippel, A Rösch, JC Simon, B Conrad, S Körner, C Windemuth-Kieselbach, L Schwarz, C Garbe, JC Becker, D Schadendorf,

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading